Myeloid leukemia after cytotoxic therapy and other hematotoxinsLARSON, Richard A.Journal of toxicology and environmental health. 2000, Vol 61, Num 5-6, pp 381-386, issn 0098-4108Conference Paper

Progress and challenges in the therapy of adult acute lymphoblastic leukemiaKEBRIAEI, Partow; LARSON, Richard A.Current opinion in hematology. 2003, Vol 10, Num 4, pp 284-289, issn 1065-6251, 6 p.Article

Recent clinical trials in acute lymphocytic leukemia by the cancer and leukemia group BLARSON, Richard A.Hematology/oncology clinics of North America. 2000, Vol 14, Num 6, issn 0889-8588, x,1367-1379 [14 p.]Article

Three New Drugs for Acute Lymphoblastic Leukemia : Nelarabine, Clofarabine, and ForodesineLARSON, Richard A.Seminars in oncology. 2007, Vol 34, Num 6, issn 0093-7754, S13-S20, SUP5Article

Management of acute lymphoblastic leukemia in older patientsLARSON, Richard A.Seminars in hematology. 2006, Vol 43, Num 2, pp 126-133, issn 0037-1963, 8 p.Article

Current use and future development of gemtuzumab ozogamicinLARSON, Richard A.Seminars in hematology. 2001, Vol 38, Num 3, pp 24-31, issn 0037-1963, SUP6Article

Advances in the treatment of adult acute lymphocytic leukemia, part IIKANTARJIAN, Hagop M; HOELZER, Dieter; LARSON, Richard A et al.Hematology/oncology clinics of North America. 2001, Vol 15, Num 1, issn 0889-8588, 225 p.Serial Issue

Advanced in the Treatment of Adult Acute Lymphocytic Leukemia, Part IKANTARJIAN, Hagop M; HOELZER, Dieter; LARSON, Richard A et al.Hematology/oncology clinics of North America. 2000, Vol 14, Num 6, issn 0889-8588, 204 p.Serial Issue

Amelanocytic Anhidrotic Alopecia Areata-like Phenotype After Allogeneic Hematopoietic Cell TransplantNTUEN KAMINSKA, Edidong Celestine; LARSON, Richard A; PETRONIC-ROSIC, Vesna et al.Archives of dermatology (1960). 2012, Vol 148, Num 8, pp 931-934, issn 0003-987X, 4 p.Article

High-dose anthracycline induction in adult acute lymphocytic leukemiaTODESCHINI, Giuseppe.Hematology/oncology clinics of North America. 2001, Vol 15, Num 1, pp v-vi, issn 0889-8588, 14 p.Article

Central nervous system involvement in adult acute lymphocytic leukemiaCORTES, Jorge.Hematology/oncology clinics of North America. 2001, Vol 15, Num 1, issn 0889-8588, vii,145-162 [19 p.]Article

Cytogenetics in adult acute lymphocytic leukemiaWETZLER, Meir.Hematology/oncology clinics of North America. 2000, Vol 14, Num 6, issn 0889-8588, viii,1237-1249 [14 p.]Article

Induction therapy of adult acute lymphocytic leukemia without the use of vincristine or prednisoneWEISS, Mark.Hematology/oncology clinics of North America. 2001, Vol 15, Num 1, issn 0889-8588, v,1-7 [8 p.]Article

Hydration/expansion and cation charge compensation modulate the brønsted basicity of distorted clay waterCERVINI-SILVA, Javiera; LARSON, Richard A; STUCKI, Joseph W et al.Langmuir. 2006, Vol 22, Num 7, pp 2961-2965, issn 0743-7463, 5 p.Article

Photochemistry in Hoagland's nutrient solutionHOTHEM, Seth D; MARLEY, Karen A; LARSON, Richard A et al.Journal of plant nutrition. 2003, Vol 26, Num 4, pp 845-854, issn 0190-4167, 10 p.Article

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)GUPTA, Pankaj; MULKEY, Flora; LARSON, Richard A et al.Investigational new drugs. 2013, Vol 31, Num 5, pp 1311-1320, issn 0167-6997, 10 p.Article

Identification of a 24-Gene Prognostic Signature That Improves the European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: An International Collaborative StudyZEJUAN LI; HEROLD, Tobias; XINAN YANG et al.Journal of clinical oncology. 2013, Vol 31, Num 9, pp 1172-1181, issn 0732-183X, 10 p.Article

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML, within the ELN Favorable genetic categoryMETZELER, Klaus H; BECKER, Heiko; POWELL, Bayard L et al.Blood. 2011, Vol 118, Num 26, pp 6920-6929, issn 0006-4971, 10 p.Article

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 studyLILLY, Michael B; OTTMANN, Oliver G; BRADLEY-GARELIK, Mary Brigid et al.American journal of hematology. 2010, Vol 85, Num 3, pp 164-170, issn 0361-8609, 7 p.Article

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyBECKER, Heiko; MARCUCCI, Guido; WU, Yue-Zhong et al.Blood. 2010, Vol 116, Num 5, pp 788-792, issn 0006-4971, 5 p.Article

Efficacy of Imatinib Dose Escalation in Patients With Chronic Myeloid Leukemia in Chronic PhaseKANTARJIAN, Hagop M; LARSON, Richard A; GUILHOT, Francois et al.Cancer. 2009, Vol 115, Num 3, pp 551-560, issn 0008-543X, 10 p.Article

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiaLE COUTRE, Philipp; OTTMANN, Oliver G; KULICZKOWSKI, Kazimierz et al.Blood. 2008, Vol 111, Num 4, pp 1834-1839, issn 0006-4971, 6 p.Article

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. CommentaryGUILHOT, Francois; APPERLEY, Jane; HEIM, Dominik et al.Blood. 2007, Vol 109, Num 10, issn 0006-4971, 4110, 4143-4150 [9 p.]Article

Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21) : A cancer and leukemia group B studyPASCHKA, Peter; MARCUCCI, Guido; KOLITZ, Jonathan E et al.Journal of clinical oncology. 2006, Vol 24, Num 24, pp 3904-3911, issn 0732-183X, 8 p.Article

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrenceLARSON, Richard A; SIEVERS, Eric L; LEOPOLD, Lance H et al.Cancer. 2005, Vol 104, Num 7, pp 1442-1452, issn 0008-543X, 11 p.Article